Leveraging their cutting-edge chemistry capabilities and unique know-how, Syntarga is creating an antibody empowering Potent Payload Technology. Through partnerships and independent efforts, they aim to generate and commercialize a portfolio of next-generation Antibody-Drug Conjugate products. With a global presence and a commitment to improving healthcare, Synthon, the parent company of Syntarga, specializes in manufacturing high-quality generic medicines. Their goal is to make treatments more affordable and increase access to important remedies. With over 90 countries approving their products, Synthon's expertise and innovative R&D position them well for the future.